https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18

 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

https://eu.vvardis.com/  

8952 Schlieren, Wagistrasse 27

At the heart of vVARDIS is the breakthrough biomimetic P11-4 peptide technology that is uniquely capable of treating early-stage caries by regenerating tooth enamel - the only tissue in the body that cannot heal itself. Backed by more than 25 years of research and more than 10 years of clinical practice, the vVARDIS technology has been peer-reviewed in more than 230 publications and is being incorporated into the curricula of renowned dental schools. This breakthrough technology, which is suitable for patients of all ages, stops and eliminates caries in its early stages while preserving the natural tooth structure. No drilling, no anesthesia and no pain.

https://omnimedica.com/  

8952 Schlieren, Lättenstrasse 27

 info@omnimedica.com

The company develops and distributes active ingredients and end products in the field of cosmeceuticals, nutritional supplements, sports, palliative medicine, dental medicine and detoxification/filter systems.